Editor's Choice
2022’s Top Clinical Advancements See Pivotal Data in NASH, Alzheimer’s, Sickle Cell Disease26 Dec 2022
Though much of the attention in the biopharma industry focuses on FDA approvals, those cannot happen without what is arguably... Continue Reading
|
2022’s Top 5 FDA Drug Approvals are Major Advancements in Cancer, Cardiovascular Disease and Rare Disorders26 Dec 2022
As we move into 2023, BioSpace takes a pause to reflect on the year gone by and some of the most remarkable... Continue Reading
|
Q/A: Podimetrics CEO Talks Preventing Diabetic Amputations26 Dec 2022
Diabetes prevention is one of the biggest challenges in the healthcare industry as more than 37 million Americans (11.3% of... Continue Reading
|
Backed by Major Health Plans, Carallel Raises $8.2M for Personalized Caregiver Support26 Dec 2022
Carallel, a Chicago, IL-based provider of human-centered guidance and digital tools for family caregivers raises a $8.2M Series A funding... Continue Reading
|
NeoCart’s Revival Continues as FDA Approves Ocugen’s Phase III Trial Design19 Dec 2022
The FDA has approved the Phase III trial design for Ocugen’s NeoCart, the company announced Friday. It’s the next step in a possible redemption... Continue Reading
|
Pangea Biomed Adds $5M for its Multi-Cancer Response Predictor19 Dec 2022
Pangea Biomed, the biotech company behind ENLIGHT, the multi-cancer response predictor improving the effectiveness of precision oncology, announced $5M in... Continue Reading
|
To Truly Address Behavioral Health Worker Shortages, We Need Telemedicine19 Dec 2022
In late September, the Senate Finance Committee released a bipartisan discussion draft bill that aims to address the nation’s crippling behavioral healthcare crisis by... Continue Reading
|
HearUSA to Carry Sony’s Over-the-Counter Hearing Aids19 Dec 2022
What You Should Know: HearUSA, America’s largest hearing care retailer, will announce the availability of OTC hearing aids from Sony... Continue Reading
|
3 Elements Required for Data Ecosystems to Drive Innovation19 Dec 2022
For years, the healthcare industry has been inundated with stories about the importance of sharing data among payers, providers, and... Continue Reading
|
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model12 Dec 2022
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries SALT... Continue Reading
|